Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.17 +2.1%	$2.97	$1.05 ▼ $3.97	$357.75M	1.92	715,214 shs	1.18 million shs
ARDX Ardelyx	$6.11	$4.58	$3.21 ▼ $7.18	$1.47B	0.68	4.67 million shs	3.65 million shs
PAHC Phibro Animal Health	$32.46 +2.9%	$28.31	$16.16 ▼ $32.95	$1.28B	0.8	251,943 shs	194,402 shs
PHVS Pharvaris	$23.12 -1.0%	$20.27	$11.51 ▼ $26.33	$1.21B	-2.81	142,735 shs	53,502 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.93%	+0.80%	-0.94%	+31.06%	+7.47%
ARDX Ardelyx	0.00%	+2.35%	+39.18%	+53.90%	-4.08%
PAHC Phibro Animal Health	+2.88%	+5.84%	+8.96%	+39.67%	+75.84%
PHVS Pharvaris	-0.99%	+3.68%	+10.94%	+44.59%	+29.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.9803 of 5 stars	3.5	1.0	0.0	0.0	2.6	0.8	0.6
ARDX Ardelyx	4.3226 of 5 stars	3.5	2.0	0.0	4.4	3.0	2.5	0.6
PAHC Phibro Animal Health	3.459 of 5 stars	0.9	2.0	2.5	1.1	2.0	3.3	2.5
PHVS Pharvaris	2.6385 of 5 stars	3.4	4.0	0.0	0.0	3.3	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	144.87% Upside
ARDX Ardelyx	3.00	Buy	$11.50	88.22% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-24.83% Downside
PHVS Pharvaris	2.83	Moderate Buy	$35.60	53.98% Upside

Current Analyst Ratings Breakdown

Latest ADCT, PAHC, PHVS, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	PHVS Pharvaris	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	PHVS Pharvaris	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$55.00 ➝ $52.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$77.25M	4.61	N/A	N/A	($1.77) per share	-1.79
ARDX Ardelyx	$333.61M	4.41	N/A	N/A	$0.58 per share	10.53
PAHC Phibro Animal Health	$1.02B	1.29	$2.17 per share	14.93	$6.34 per share	5.12
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.23	N/A	19.71	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	41.62	15.46	0.53	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.36	N/A	N/A	N/A	N/A	-69.09%	-63.34%	N/A

Latest ADCT, PAHC, PHVS, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/12/2025	Q2 2025	PHVS Pharvaris	-$0.87	-$0.94	-$0.07	-$0.94	N/A	N/A
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.48%	N/A	61.54%	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Latest ADCT, PAHC, PHVS, and ARDX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
ARDX Ardelyx	1.44	4.30	4.03
PAHC Phibro Animal Health	2.67	2.91	1.23
PHVS Pharvaris	N/A	8.33	8.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ARDX Ardelyx	58.92%
PAHC Phibro Animal Health	99.34%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
ARDX Ardelyx	4.80%
PAHC Phibro Animal Health	50.07%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable

ADCT, PAHC, PHVS, and ARDX Headlines

Recent News About These Companies

Pharvaris (NASDAQ:PHVS) Upgraded to Hold at Zacks Research

August 22 at 9:58 AM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Shares Up 6.2% - Here's What Happened

August 21 at 4:50 PM | marketbeat.com

Pharvaris (NASDAQ:PHVS) Upgraded at Zacks Research

August 21 at 2:00 AM | americanbankingnews.com

Pharvaris N.V. (NASDAQ:PHVS) Short Interest Update

August 20 at 9:30 AM | marketbeat.com

Pharvaris Advances Clinical Pipeline with Strong Financials

August 20 at 5:09 AM | msn.com

What is Leerink Partnrs' Estimate for Pharvaris Q3 Earnings?

August 19, 2025 | marketbeat.com

Q3 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

August 19, 2025 | americanbankingnews.com

Cantor Fitzgerald Increases Earnings Estimates for Pharvaris

August 17, 2025 | marketbeat.com

Wedbush Comments on Pharvaris' Q3 Earnings (NASDAQ:PHVS)

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Lifts Earnings Estimates for Pharvaris

August 17, 2025 | americanbankingnews.com

Wedbush Issues Positive Estimate for Pharvaris Earnings

August 17, 2025 | americanbankingnews.com

Wedbush Predicts Pharvaris' FY2029 Earnings (NASDAQ:PHVS)

August 16, 2025 | marketbeat.com

JMP Securities Cuts Pharvaris (NASDAQ:PHVS) Price Target to $52.00

August 16, 2025 | americanbankingnews.com

JMP Securities Lowers Pharvaris (NASDAQ:PHVS) Price Target to $52.00

August 15, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

August 14, 2025 | marketbeat.com

Pharvaris price target lowered to $52 from $55 at Citizens JMP

August 13, 2025 | msn.com

Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

August 12, 2025 | msn.com

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | taiwannews.com.twT

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025 | globenewswire.com

Pharvaris (PHVS) to Release Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Pharvaris (PHVS) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, PAHC, PHVS, and ARDX Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.16 +0.07 (+2.10%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.20 +0.03 (+0.95%)

As of 08/22/2025 06:14 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Ardelyx NASDAQ:ARDX

$6.11 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.15 +0.04 (+0.64%)

As of 08/22/2025 07:58 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$32.46 +0.91 (+2.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$32.44 -0.02 (-0.05%)

As of 08/22/2025 04:20 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Pharvaris NASDAQ:PHVS

$23.12 -0.23 (-0.99%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$23.18 +0.05 (+0.24%)

As of 08/22/2025 04:10 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time